Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal
hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately …

Current therapies against cancer utilize the patient's immune system for tumor eradication.
However, tumor cells can evade immune surveillance of CD8+ T and/or natural killer (NK) …

Inhibition of JAK1 or JAK2 in human tumor cells was previously shown to increase
susceptibility of these cells to NK cell lysis. In the present study, we examined the cellular …

Immune suppression, exhaustion, and senescence are frequently seen throughout disease
progression in acute myeloid leukemia (AML). We conducted a phase II study of high-dose …

The development of immune checkpoint inhibitors represents a major breakthrough in the
field of cancer therapeutics. Pursuant to their success in melanoma and numerous solid …

Immunotherapies, such as chimeric antigen receptor T cells, bispecific antibodies, and
immune checkpoint inhibitors, have emerged as promising modalities in multiple …

Interferon (IFN)-γ is the uppermost cytokine implicated in anti-tumor immunity. With its
cytostatic, pro-apoptotic and immune-provoking effects, IFN-γ plays a central role in the …

Immune responses generated against malignant cells have the potential to inhibit tumor
growth, or even eliminate transformed cells before a tumor forms. However, immune …

CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) accumulate in bone marrow
microenvironment in acute myeloid leukemia (AML). However, little is known about how the …

The treatment of patients with acute myeloid leukemia (AML) with targeted immunotherapy is
challenged by the heterogeneity of the disease and a lack of tumor-exclusive antigens …